Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2065326 | 0.97 | KMT2A (0.46) | KMT2AALDH1A1GLAMAPTMEN1 | |
| SCHEMBL2064796 | 0.91 | CGAS (0.39) | KMT2AALDH1A1GLAMAPTMEN1 | |
| SCHEMBL2065579 | 0.91 | GSK3B (0.46) | KMT2AALDH1A1GLAMAPTMEN1 | |
| SCHEMBL2065165 | 0.90 | TSHR (0.42) | KMT2AALDH1A1MAPTMEN1TSHR | |
| SCHEMBL2066082 | 0.89 | CRBN (0.47) | KMT2AALDH1A1MEN1GSK3B | |
| SCHEMBL2065921 | 0.89 | F10 (0.45) | ALDH1A1HCRTR1CGAS | |
| SCHEMBL2066338 | 0.89 | KCNMA1 (0.46) | KMT2AALDH1A1MAPTMEN1LMNA | |
| SCHEMBL2065434 | 0.89 | GSK3B (0.45) | KMT2AMEN1TSHRLMNAHCRTR1 | |
| SCHEMBL2065553 | 0.89 | KMT2A (0.43) | KMT2AALDH1A1MAPTMEN1LMNA | |
| SCHEMBL4952879 | 0.89 | MEN1 (0.47) | KMT2AALDH1A1MEN1KDM4ECGAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148364-B2 | Substituted bicyclic pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | claimed |
| EP-1957492-B1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | claimed |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | claimed |
| US-8148364-B2 | Substituted bicyclic pyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-04-03 | — | — | US | disclosed |
| EP-1957492-B1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI AVENTIS (FR) | 2010-11-10 | — | — | EP | disclosed |
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036427-A1 | SUBSTITUTED BICYCLIC PYRIMIDONE DERIVATIVES | GSK3B, GSK3A, PSEN1 | KMT2A 1782/4885ALDH1A1 1204/4885GLA 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.